<DOC>
	<DOCNO>NCT00914927</DOCNO>
	<brief_summary>The purpose study evaluate efficacy once-daily Oral E5501 subject chronic liver disease thrombocytopenia prior elective surgical diagnostic procedure , evaluate safety short-term administration E5501 evaluate pharmacokinetics ( PK ) E5501 .</brief_summary>
	<brief_title>Once-Daily Oral E5501 Tablets Used Subjects With Chronic Liver Diseases Thrombocytopenia Prior Elective Surgical Diagnostic Procedures</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Key 1 . Males females ≥ 18 year age 2 . Thrombocytopenia ( define platelet count ≥ 10,000 ≤ 50,000 ( +15 % ) /mm3 ) 3 . Model EndStage Liver Disease ( MELD ) score ≤ 24 4 . Chronic liver disease due one follow three etiology : Chronic Viral Hepatitis one follow category Chronic Hepatitis C ( define presence antihepatitis C virus [ HCV ] antibodies and/or detectable serum HCV ribonucleic acid [ RNA ] level ) OR chronic Hepatitis B ( define presence hepatitis B surface antigen [ HBsAg ] and/or detectable serum hepatitis B virus [ HBV ] deoxyribonucleic acid [ DNA ] ) OR chronic Hepatitis B C coinfection ( defined bullet point ) OR chronic Hepatitis C history alcohol abuse OR chronic Hepatitis B history alcohol abuse NASH diagnose : absence serologic evidence viral hepatitis convince evidence history minimal alcohol consumption , histologic picture steatohepatitis OR histology unavailable , clinical , radiographic laboratory evidence NASH Alcoholic liver disease diagnose : absence serologic evidence viral hepatitis history heavy alcohol consumption histologic picture alcoholic liver disease OR histology unavailable , clinical , radiographic laboratory evidence hepatitis combine year excessive alcohol intake 5 . Subjects schedule undergo elective invasive procedure 1 4 day post last dose study drug . 6 . Adequate renal function evidence calculated creatinine clearance ≥50 mL/minute per Cockcroft Gault formula 7 . Life expectancy ≥3 month Key 1 . Hepatic encephalopathy effectively treat . 2 . Platelet transfusion within 7 day prior first dose study drug 3 . Received blood product , eg , FFP cryoprecipitate 7 day prior first dose study drug 4 . Have surgical diagnostic procedure schedule Randomization Phase ( Day 1 Day 8 ) study 5 . Interferon use within 2 week Day 1 6 . Hormonal contraceptive use within 60 day study entry 7 . History human immunodeficiency virus ( HIV ) infection 8 . Any prohibited concomitant medication therapy discontinue Visit 1 9 . Active alcohol abuse , active alcohol dependence syndrome , drug abuse , drug dependence within 6 month study start ( unless participate controlled rehabilitation program ) 10 . Acute alcoholic hepatitis ( chronic alcoholic hepatitis allow ) within 6 month study start 11 . History primary hematologic disorder 12 . History arterial venous thrombosis , include thrombosis part splenicmesenteric system 13 . Any evidence current portal vein thrombosis ( PVT ) detect Doppler sonography appropriate MRI/CT image Screening and/or within approximately 30 day prior Screening 14 . Any acute/active bleeding ( gastrointestinal [ GI ] , central nervous system [ CNS ] , etc ) 15 . Uncompensated congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) 16 . Prediagnosed Immune Thrombocytopenic Purpura ( ITP ) 17 . History Myelodysplastic Syndrome ( MDS ) 18 . Females pregnant ( positive βhCG test ) breastfeed 19 . Current use recreational drug 20 . Posttransplant patient 21 . Subjects participate another investigational trial within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>chronic liver disease</keyword>
</DOC>